A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design by Chen, Yuxin et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2013-09-01 
A novel rabbit monoclonal antibody platform to dissect the 
diverse repertoire of antibody epitopes for HIV-1 Env immunogen 
design 
Yuxin Chen 
University of Massachusetts Medical School Worcester 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Immunology of Infectious Disease Commons, Immunoprophylaxis and Therapy Commons, 
Infectious Disease Commons, Virology Commons, and the Virus Diseases Commons 
Repository Citation 
Chen Y, Vaine M, Wallace A, Han D, Wan S, Seaman MS, Montefiori DC, Wang S, Lu S. (2013). A novel 
rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env 
immunogen design. Open Access Articles. https://doi.org/10.1128/JVI.00837-13. Retrieved from 
https://escholarship.umassmed.edu/oapubs/2414 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
  Published Ahead of Print 17 July 2013. 
2013, 87(18):10232. DOI: 10.1128/JVI.00837-13. J. Virol. 
Wang and Shan Lu
ShixiaShengqin Wan, Michael S. Seaman, David Montefiori, 
Yuxin Chen, Michael Vaine, Aaron Wallace, Dong Han,
 
Immunogen Design
of Antibody Epitopes for HIV-1 Env
Platform To Dissect the Diverse Repertoire 
A Novel Rabbit Monoclonal Antibody
http://jvi.asm.org/content/87/18/10232
Updated information and services can be found at: 
These include:
REFERENCES
http://jvi.asm.org/content/87/18/10232#ref-list-1at: 
This article cites 63 articles, 33 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 N
ovem
ber 17, 2014 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 N
ovem
ber 17, 2014 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
A Novel Rabbit Monoclonal Antibody Platform To Dissect the Diverse
Repertoire of Antibody Epitopes for HIV-1 Env Immunogen Design
Yuxin Chen,a Michael Vaine,a Aaron Wallace,a Dong Han,a Shengqin Wan,a Michael S. Seaman,b David Monteﬁori,c Shixia Wang,a
Shan Lua
Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USAa; Department of Medicine, Center for Virology and Vaccine
Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USAb; Department of Surgery, Duke University Medical Center, Durham,
North Carolina, USAc
Themajority of available monoclonal antibodies (MAbs) in the current HIV vaccine field are generated fromHIV-1-infected
people. In contrast, preclinical immunogenicity studies have mainly focused on polyclonal antibody responses in experimental
animals. Although rabbits have been widely used for antibody studies, there has been no report of using rabbit MAbs to dissect
the specificity of antibody responses for AIDS vaccine development. Here we report on the production of a panel of 12MAbs
from a New ZealandWhite (NZW) rabbit that was immunized with an HIV-1 JR-FL gp120 DNA prime and protein boost vacci-
nation regimen. These rabbit MAbs recognized a diverse repertoire of envelope (Env) epitopes ranging from the highly immuno-
genic V3 region to several previously underappreciated epitopes in the C1, C4, and C5 regions. NineMAbs showed cross-reactiv-
ity to gp120s of clades other than clade B. Increased somatic mutation and extended CDR3 were observed with Ig genes of several
molecularly cloned rabbit MAbs. Phylogenic tree analysis showed that the heavy chains of MAbs recognizing the same region on
gp120 tend to segregate into an independent subtree. At least three rabbit MAbs showed neutralizing activities with various de-
grees of breadth and potency. The establishment of this rabbit MAb platform will significantly enhance our ability to test opti-
mal designs of Env immunogens to gain a better understanding of the structural specificity and evolution process of Env-specific
antibody responses elicited by candidate AIDS vaccines.
Despite 30 years of intensive research, no effective vaccine for-mulations are available to prevent the transmission of human
immunodeficiency virus type 1 (HIV-1). The recent RV144 trial
showed an estimated 31.2% efficacy of protection (1) and, most
significantly, revealed a positive correlation of protection with the
presence of serum IgG binding antibodies (Abs) to variable region
2 (V2) of the envelope (Env) glycoprotein of HIV-1 (2, 3). These
results confirmed the role of antibodies in an effective HIV-1 vac-
cine but also raised serious questions about the lack of knowledge
on the diversity and potential functions of Env-specific antibodies
present in an immunized serum.
Antibody research in the HIV-1 vaccine field has focused for a
long time on the study of neutralizing human monoclonal anti-
bodies (HMAbs) generated from HIV-1-infected patients. While
these studies have provided remarkable information on the struc-
tural requirements for HMAbs, such unusually broadly neutraliz-
ing (bnHMAbs) can be identified in only 2% to 4% of the infected
population and only after 2 or 3 years of infection (4–7). In con-
trast, the role of nonneutralizing antibodies targeting other areas
of Env was virtually unknown prior to the study of antibody re-
sponses in RV144 volunteers (2, 8). Since it is a lengthy process to
advance a candidate vaccine to human trials, most preclinical vac-
cine studies on the diversity and quality of antibody responses are
conducted first in experimental animals.
Previously, we reported the elicitation of cross-clade neutral-
izing antibody responses when a DNA prime-protein boost im-
munization approach was adopted to deliver a polyvalent Env
immunogen formulation in animal and human studies (9–11).
Further epitope mapping and antibody competition analyses
identified quality differences between the immune sera elicited by
the DNA prime-protein boost approach and the protein-alone
approach (12, 13). However, these studies were conducted using
polyclonal sera and results from these studies were unable to link
the observed antibody activities with a particular antibody com-
ponent in a polyclonal serum.
Here we report the use of a recombinant rabbit monoclonal
antibody (RMAb) platform tomonitor the specificity andneutral-
izing activities of antibodies elicited by a candidate HIV-1 Env
immunogen. Historically, rabbit has been an attractive animal
model for antibody studies and has been used more recently in
HIV vaccine research because rabbit is highly immunogenic in
responding to various immunization regimens to produce high-
titer antibody responses. It was shown that only RMAbs were able
to provide high-quality detection using certain difficult epitopes,
such as those in tissue section samples and HIV particles (14–16).
Rabbit antibodies usually carry limited background reactivity to
testing antigens. Rabbits provide a large volume of immune sera
for a wide range of antibody assays, while the other common ex-
perimental animal species, such as mouse or rat, can provide
only a limited volume of immune sera and high background in
functional antibody assays. Moreover, rabbit antibodies, but
not those from mouse, are able to generate long CDR3 regions,
which is important for many neutralizing antibodies against
HIV-1 (17, 18).
In the current pilot study, a panel of 12 HIV-1 Env-specific
rabbit hybridoma cell lines were produced that can recognize a
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wide range of Env epitopes. Furthermore, their heavy-chain and
light-chain genes were cloned and their genetic features were an-
alyzed. RMAbs were produced from these rabbit Ig clones, and
their epitope specificity, binding affinity, and neutralization activ-
ities were determined.
MATERIALS AND METHODS
HIV-1 gp120 DNA vaccine. The codon-optimized gene segment coding
for the gp120 region of HIV-1 isolate JR-FL (19) was subcloned into the
pJW4303 DNA vaccine vector for the DNA priming phase of the immu-
nization, as previously reported (10). JR-FL gp120 DNA plasmid was
produced in the HB101 strain of Escherichia coli and then purified using a
Qiagen Plasmid Mega kit (catalog no. 12183).
HIV-1 gp120 protein vaccines. Recombinant HIV-1 gp120 protein
vaccine was produced from Chinese hamster ovary (CHO) cells. Secreted
gp120 proteins from stably transfected CHO cell lines were harvested and
purified over a lectin column.
Rabbit immunizations. New Zealand White rabbits (6 to 8 weeks of
age) were purchased fromMillbrook Farm (Amherst, MA) and housed in
the animal facilitymanaged by the Department of AnimalMedicine at the
University of Massachusetts Medical School (UMMS). All procedures
were carried out by following animal research guidelines and approved by
the IACUC. Each rabbit was immunized three times at weeks 0, 2, and 4
with JR-FL gp120 DNA vaccine via a Bio-Rad Helios gene gun applied to
the shaved abdominal skin (36 g/immunization). Rabbits were then
boosted twice intramuscularly at weeks 8 and 12 with 50 g JR-FL gp120
recombinant protein formulated in incomplete Freund’s adjuvant (IFA)
for each boost. After a 4-month resting period, one rabbit from the study
groupwas boosted again with the same JR-FL gp120DNA vaccine at week
28 followed by an intravenous 400g JR-FL gp120 protein immunization
at week 32.
Rabbit hybridoma production. Spleens were collected from sacri-
ficed rabbits 4 days after the final protein boost and sent to a subcontractor
(Epitopmics) for the production of hybridoma cells, according to the
company’s established procedure. The rabbit hybridoma fusion partner
cells were developed previously (20) and further optimized to facilitate the
generation of rabbit hybridoma cell lines (US patents 7,575,896 B2 [21]
and 7,732,168 B2 [22]).
ELISA. Supernatant from hybridoma culture was sent back to UMMS
for screening of gp120-specific antibodies. An enzyme-linked immu-
nosorbent assay (ELISA) was conducted in 96-well microtiter plates
(Corning, NY), which were first incubated with concanavalin A (ConA)
(5g per well in 100l of phosphate-buffered saline [PBS], pH 7.2) for 1
h and then coated with 100 l of gp120 antigen (1 g/ml) from a tran-
siently transfected 293T cell supernatant. Plates were washed five times
with ELISA washing buffer (EWB; PBS containing 0.1% Triton-X) and
blocked overnight at 4°C in PBS containing whey dilution buffer (4%
whey by weight) and 5% powdered milk. The following morning, plates
were washed five times in EWB. Hybridoma supernatants or serially di-
luted rabbitmonoclonal antibodies were added to the wells in a volume of
100l. Plates werewashed five times in EWBand incubatedwith 100l of
biotinylated anti-rabbit secondary antibody (Vector Laboratories BA-
1000) at 1.5 g/ml for 1 h at room temperature. Plates were washed five
times with EWB and incubated with 100 l of a streptavidin-conjugated
horseradish peroxidase (Vector Laboratories, catalog no. SA-5004) at 500
ng/ml. Plateswerewashedfive timeswith EWBanddeveloped for 3min in
100 l of a 3,3=5,5=-tetramethylbenzidine substrate solution (Sigma; cat-
alog no. T3405). The reaction was stopped with 25 l of 2N H2SO4.
For the peptide epitope assay, 96-well microtiter plates were coated
with overlapping peptides of HIV-1 consensus subtype B Env at 4 g/ml
for 1 h and blocked overnight. Hybridoma supernatants (100 l) were
then added to the peptide wells. Bound antibody was detected using an
anti-rabbit IgG secondary antibody, as described above.
Western blot analysis. The JR-FL gp120 antigen used in the Western
blot analysis was obtained from 293T cells transiently transfected with a
JR-FL gp120-expressing DNA vaccine, as previously reported (12). The
gp120 antigens were subjected to SDS-PAGE and blotted onto a polyvi-
nylidene difluoride (PVDF) membrane, as previously described (11).
Blocking of the PVDF membrane was done with 0.1% I-Block (Tropix,
Bedford,MA). Themembranes were incubated with hybridoma superna-
tants at a 1:100 dilution for 45 min and subsequently reacted with AP-
conjugated goat anti-rabbit IgG (Tropix, Bedford, MA) at a 1:5,000 dilu-
tion for 30 min. Membranes were washed with blocking buffer after each
step. Western Light substrate was then applied to the membranes for 5
min. Once the membranes were dry, X-ray films were exposed to the
membrane and developed using a Kodak processor.
Cloning and expression of rabbitMAb IgG genes. Full-length heavy-
chain and light-chain gene transcripts of rabbit MAb were isolated by
one-step reverse transcriptase PCR (RT-PCR) amplification of hybrid-
oma cell RNA. Primers were designed to target the conserved regions of
rabbit IgG genes using heavy-chain primers (forward, 5=-CCGTCCAAG
CTTHindIIIATGGAGACTGGGCTGCGCTGGC-3=; reverse, 5=-CAACAA
GGATCCBamHICTATTTACCCGGAGAGCGGGAG-3=; recognition sites
for restriction enzymes are underlined) and light-chain primers (forward,
5=-CCGTCCAAGCTTHindIIIATGGACACGAGGGCCCCCACTC-3=; re-
verse, 5=-CAACAAGGATCCBamHICTAACAGTCACCCCTATTGAAG
C-3=). Specifically, one-step RT-PCRwas carried out by adding 6l H2O,
12.5l reactionmix, 2.5l each of the forward and backward primers, 0.1
l RNase inhibitor, 5l RNA template, and 0.5l RT–Platinum Taqmix
(Invitrogen; catalog no. 10928-042). The thermocycle program was 50°C
for 30min and 94°C for 2min, followed by 30 cycles of 94°C for 15 s, 55°C
for 30 s, 68°C for 48 s, and 68°C for 5 min, followed by 4°C for 10 min.
Antibody heavy-chain and light-chain gene products were separately
cloned into a mammalian expression vector, pJW4303. For expression,
equal amounts of heavy- and light-chain plasmid DNAs were transfected
with 293Fectin into Freestyle 293F cells (Invitrogen). The cell culture
supernatant containing the secreted rabbit IgG was harvested 2 days
after transfection and purified using protein A-Sepharose columns
(GE Healthcare).
Analysis of rabbit MAb heavy-chain and light-chain sequences. Se-
quencing analysis was conducted with the rabbit heavy-chain and light-
chain genes of rabbitMAb.ClustalWwas used, and themultiple-sequence
alignments were done to construct phylogenetic trees using maximum-
likelihoodmethods. The trees were then graphically edited (23). Antibody
germ line usage, mutation frequency, and CDR3 length were determined
by means of IMGT/V-QUEST (24).
Neutralization assays. In-house neutralization assays were done as
previously described (25). HIV pseudoviruses were first produced and
titrated. Briefly, equimolar quantities of a plasmid expressing gp160 from
theHIV-1 Env of interest and the pSG3EnvHIVbackbonewere cotrans-
fected into HEK 293T cells. At 48 h after transfection, supernatants were
harvested and cleared of cell debris by low-speed centrifugation. Pro-
duced pseudoviruses were titrated on TZM-bl cells using a 2-fold increase
above background levels of luciferase activity as a positive cutoff.
For an in-house neutralization assay, pseudovirus (200 50% tissue
culture infective doses [TCID50]) was incubated with the rabbit sera or
rabbit MAb for 1 h at 37°C. The virus-MAb mix was then added to 105
TZM-bl cells in a final concentration of 20 g/ml DEAE dextran. Plates
were incubated at 37°C for 48 h and developed with luciferase assay re-
agent according to themanufacturer’s instruction (Promega).Neutraliza-
tion was calculated as the percent change in luciferase activity in the pres-
ence of preimmune sera versus that of luciferase activity in the presence of
immune sera as follows: [(preimmune RLUs  immune RLUs)/(preim-
mune RLUs)] 100 (where RLU relative light units).
Selected RMAbswere tested in a high-throughput neutralization assay
using the PhenoSense assay at Monogram Biosciences (South San Fran-
cisco, CA) as previously reported (12).
Additional neutralization assays were conducted at Duke University
and at Beth Israel Deaconess Medical Center, Harvard Medical School,
Rabbit MAb Platform for HIV-1 Vaccine Design
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according to their established protocols as described in previous reports
(10).
Binding kinetics of rabbit MAbs. The kinetics of binding of rabbit
MAb to five representative gp120s fromHIV-1 clades A to E were studied
using a ForteBio Octet QKe instrument based on biolayer interferometry
(BLI) measurements in a 96-well format following the manufacturer’s
instructions. Protein A-coated tips (ForteBio) were loadedwith rabbitMAbs
at 10g/mldiluted in thebuffer of PBS–0.1%bovine serumalbumin (BSA)–
0.002% Tween 20. After capture, a 1-min wash in loading buffer removed
excess unbound Ab to establish a new baseline signal. The biosensor tip was
then put into wells containing the selected gp120 proteins at 3-fold serially
diluted concentrations of from 100 to 11 nM in loading buffer.
On-rate rabbit MAb-gp120 association was measured using a 3-min
interval followed by putting the sensor in wells containing regenerating
buffer (500 mM phosphoric acid) to measure the (off-rate) dissociation
rate over a 10-min interval. Equilibriumdissociation constant (KD) values
were calculated as the ratio of off-rate values to on-rate values. The sen-
sorgrams were corrected with the blank reference and fitted with ForteBio
Data Analysis software package 7.0 using a 1:1 binding model with the
global fitting function (grouped by color [Rmax]).
RESULTS
Generation of HIV-1 Env-specific hybridoma cell lines from a
rabbit immunized with the DNA prime-protein boost JR-FL
gp120 vaccine. In this pilot study to explore the feasibility of pro-
ducing recombinant rabbit MAb specific for HIV-1 Env, one
NZW rabbit (9) was used for MAb isolation and characterization.
During the initial immunogenicity study, this rabbit received
three DNA inoculations followed by two inoculations with gp120
protein from HIV-1 JR-FL (Fig. 1). By the time we decided to
produceRMAb from this rabbit, it had been 16weeks since the last
immunization. Therefore, this rabbit was boosted further with a
one-time JR-FL gp120 DNA immunization and a one-time re-
combinant JR-FL gp120 protein immunization separated by 4
weeks. Four days after the final protein boost, the rabbit spleen
was harvested and sent to a subcontractor for production of hy-
bridoma cells (Fig. 1).
A total of 57 hybridoma cells (multiclonal stage) were screened
for their supernatant reactivity to the JR-FL gp120 antigen (Fig. 2).
Among them, 36 (63%) tested positive by ELISA, including 2 (R39
and R47) that were considered weakly positive (Fig. 2A). Western
blot analysis further confirmed that a smaller fraction (17 hybrid-
oma cells; 30%) had various levels of positivity against denatured
JR-FL gp120 antigen (Fig. 2B). Based on the above screening re-
sults, a panel of 12 hybridoma cell lines (lines 13, 15, 20, 27, 28, 31,
35, 41, 43, 52, 53, and 56) was selected for further production of
stable hybridoma cells (monoclonal stage), including three that
recognized only native gp120 proteins (R27, R31, and R52), with
the rest binding to both native and denatured gp120 proteins.
Diverse epitope profiles of gp120-specific RMAbs elicited by
JR-FL gp120 immunogen.The epitope specificity of these RMAbs
was determined by an ELISA against linear peptides (15 amino
acid -aa) residues eachwith 11 aa overlapping) spanning the entire
length of consensus gp120 fromgroupBofHIV-1. These 12 rabbit
hybridoma cell lines could be divided into 5 groups based on their
antigen epitope specificity (Fig. 3).
(i) V3-specific hybridomas—R20, R43, and R56 (Fig. 3A).
These hybridomas recognized two different epitopes within V3
region. One hybridoma, R56, recognized the V3 crown, the prin-
cipal target for most anti-V3 MAbs isolated from patients chron-
ically infected with HIV-1. The other hybridomas, R20 and R43,
recognized the C-terminal portion of the V3 region, an epitope
not commonly seen by human MAbs but recently described as
part of a key neutralizing epitope for several highly potent human
MAbs, such as PGT128 (26).
(ii) C4-specific hybridoma—R53 (Fig. 3B). Based on the
epitope peptide sequence, R53 binds to the bridging sheet of
gp120, a rare epitope reported only in a mouse study in the early
days of HIV-1 research (27, 28). One unique feature of R53 is that
it can bind to two discontinuous linear epitopes in the C1 and C4
regions, although there is limited sequence homology between
these two peptides.
(iii) C5-specific hybridoma—R13 (Fig. 3C). This hybridoma
binds to the far C terminus of gp120, a region known to be immu-
nodominant (29).
(iv) C1-specific hybridomas—R15, R35, and R41 (Fig. 3D).
Supernatants from these three hybridoma cell lines were able to
bind to the same three constitutive peptides in the first constant
region of HIV-1 Env.
(v) Hybridomas with an unknown epitope(s)—R27, R28,
R31, and R52 (Fig. 3E). These RMAbs did not bind to any of the
peptides included in the overlapping M-group Env peptide pool.
R27, R31, and R52 may recognize conformational epitopes, as
they showed positive ELISA binding to ConA-captured JR-FL
gp120 (Fig. 2A) but no binding as observed byWestern blotting to
the same but denatured gp120 antigen (Fig. 2B). For R28, because
it showed positive binding by both ELISA andWestern blot anal-
ysis to JR-FL gp120, it is possible that R28 can recognize only a
JR-FL-specific linear peptide that may be different from the se-
quences of the consensus clade B overlapping peptides.
FIG 1 Schematic representation of the rabbit immunization schedule. The
rabbit was given HIV Env-encoding DNA three times at 2-week intervals fol-
lowed by two (monthly) matched protein boosts. After a 16-week resting pe-
riod, this rabbit was further boosted with 1DNA and 1 protein boost. The
rabbit spleen was harvested 4 days after the final protein boost to generate
hybridoma cell lines.
FIG 2 Initial screen of 36 multiclonal stages of hybridoma cell lines by their
binding to HIV-1 JR-FL gp120 protein. (A) Binding of rabbit hybridoma su-
pernatants to HIV-1 JR-FL gp120 protein was tested by ELISA. The rabbit
serum samples prior to immunization and at week 14 served as the negative
() and positive () controls, respectively. OD450nm, optical density at 450
nm. (B) Testing hybridoma supernatants against JR-FL gp120 protein by
Western blotting. The positive and negative controls were the same as de-
scribed for panel A.
Chen et al.
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Crystal structures have been produced for several RMAbs with
known linear epitopes described in the current study, which con-
firmed the epitopes we identified in peptide-mapping ELISA. In
particular, three RMAbs (R20, R56, and R53) have been cocrys-
talized with their respective targeted peptides, as described above
for the epitope-mapping analysis, confirming the accuracy of the
mapping of epitopes by ELISA (65).
Broad binding profile and high affinity of RMAbs for gp120
proteins from different clades of HIV-1. The gene transcripts of
the full-length IgG heavy chains and light chains from the above-
described RMAbs were cloned from these hybridoma cells by RT-
PCR and further subcloned into amammalian protein expression
vector. Individual RMAbs were produced from 293T cells tran-
siently transfected with these RMAb-expressingmolecular clones.
RMAbswere individually characterized for their ability to bind
to a panel of five recombinant gp120 proteins (92UG037, JR-FL,
93MW965, 92UG021, and consensus AE Env, representing clades
A, B, C, D, and E, respectively) (Fig. 4). All isolated rabbit MAbs
were able to bind well to JR-FL gp120 by ELISA but had different
levels of binding against other gp120 antigens. Among the V3-
specific RMAbs, R56 binds to four gp120 proteins but not to that
from the cladeD isolate, 92UG021. The tip of theV3 loop for clade
D gp120, 92UG021, has a sequence (GVGR) that is very different
from the more common GPGR or GPGQ sequences seen with
other clades, in addition to having unique sequences immediately
upstreamof theV3 tip (Fig. 5). The other twoV3RMAbs, R20 and
R43, bind gp120 proteins from JR-FL and the clade A isolate,
92UG037, better than they bind the other three gp120 proteins
from the clade C, D, and E isolates. This is also consistent with
overlapping peptide ELISA (Fig. 3) and phylogenic lineage (Fig. 6)
results, which showed that R20 and R43 grouped together in both
analyses. Such data do not indicate that these two MAbs can be
used to differentiate Env from different subtypes.
R53 is one RMAb that was broadly reactive with all five gp120
proteins from different clades. In contrast, C1-targeted RMAbs
(R15, R41, and R35) uniformly bind to two gp120 proteins from
clade B (JR-FL) and clade A (92UG037) with high efficiency.
Three RMAbs recognizing conformational epitopes, R52, R31,
and R27, appeared to be highly specific to JR-FL gp120, whereas
low to no detectable was observed for the other four gp120 pro-
FIG 3 Diverse repertoire of gp120-specific rabbit monoclonal hybridoma supernatants revealed by ELISA with plates coated with individual consensus B gp120
overlapping peptides. RMAbs were classified into the following five groups: V3 specific (R20, R43, and R56) (A); C4 specific (R53) (B); C5 specific (R13) (C); C1
specific (R15, R35, and R41) (D); and unknown epitopes (R27, R31, R52, and R28) (E). (F) List of identified epitope sequences for selected rabbit hybridoma cell
lines.
Rabbit MAb Platform for HIV-1 Vaccine Design
September 2013 Volume 87 Number 18 jvi.asm.org 10235
 o
n
 N
ovem
ber 17, 2014 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
teins tested. R28, which targeted an unknown linear epitope, was
broadly reactive to all five gp120 proteins, but the overall binding
affinity was low, especially to gp120 protein from the clade A iso-
late, 92UG037.
A more detailed analysis of binding kinetics, including the
binding affinity of these RMAbs, was further performed using a
ForteBio instrument based on recently developed biolayer inter-
ferometry (BLI) technology. This system is similar to the tradi-
tional Biacore technology but is more user-friendly and can si-
multaneously process a large number of samples. Actual
measurements for three RMAbs (R15, R53, and R56) are shown in
Fig. 7. All RMAbs exhibited remarkably high binding affinity to
JR-FL gp120, with KD ranging from 0.02 nM to 4.47 nM (Fig. 7).
Gene sequence analysis ofHIV-1 gp120-specific RMAbs.The
full-length IgG heavy-chain and light-chain genes of the RMAbs
were sequenced. Germ line family usage, mutation frequency, and
CDR3 length in heavy-chain and light-chain genes were deter-
minedusing IMGTandV-QUEST (Fig. 8 andTable 1). Consistent
with a recent report (30), most of the isolated RMAb heavy-chain
genes preferentially utilized IGHV1S40*01 (IMGT numbering
system) or a3-VH1 (Kabat numbering system) as the germ line
family gene whereas only R13 and R31 used IGHV1S45*01
(IMGT numbering system) or a3-VH4 (Kabat numbering sys-
tem). For the light-chain genes, diverse germ line families were
utilized to generate gp120-specific MAbs.
Somatic hypermutation (SHM) is a key parameter in evaluat-
ing antibody affinity maturation. In the most studied model of
influenza immunization, the mean heavy-chain variable (VH)
gene mutation frequency of human antibodies induced by re-
peated vaccination is 5% (31, 32). Among 12 gp120-specific
RMAbs identified in the current study, heavy-chain V genes ex-
hibited an average SHM rate of 14.6% 9.2% (ranging from 5%
to 27%) at the amino acid level, while light-chain V genes exhib-
ited an average SHM rate of 9.25% 1.5% (ranging from 7% to
12%), indicating that the immunization regimen used in this
study was effective in stimulating a high SHM rate for gp120 an-
tigen-specific Ab genes (Table 1). The mutated amino acids for
heavy chains were mainly distributed in the CDR1 and CDR2
regions, while SHM occurred across the light-chain kappa gene
(Fig. 8). Examination of the heavy-chain CDR3 region revealed an
average length of 10.9 6.5 aa (ranging from 6 to 23 aa), and the
light-chain CDR3 region contained an average of 11.5  1.7 aa
(ranging from 8 to14 aa) (Table 1), compatible with rabbit MAbs
elicited from immunization, as previously reported (33).
To define the genetic relationship of these RMAbs, phyloge-
FIG5 V3 region protein sequences from isolates JR-FL, 92UG037, 93MW965,
92UG021, and consensus AE (AE cons). The residue position refers to the
HXB2 strain. The R56 epitope is highlighted in orange, and the R20 epitope is
in blue. The amino acids within the V3 region that differed from those within
the JR-FL strain are highlighted in red.
FIG 6 Phylogenetic tree of heavy-chain (left) and light-chain (right) gene
sequences constructed using the maximum-likelihood method. V3-specific
RMAbs are highlighted in red, C1-specific MAbs in orange, C4-specific MAbs
in cyan, C5-specific MAbs in blue, and conformational/unknown RMAbs in
black.
FIG 4 The reactivity of 12 RMAbs with a panel of representative gp120 proteins revealed by ELISA. HIV-1 Env gp120 proteins were derived from the following
isolates: 92UG037, JR-FL, 93MW965, 92UG021, and consensus AE. Conc, concentration.
Chen et al.
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netic trees were constructed based on heavy-chain and light-chain
gene sequences using the maximum-likelihood method (Fig. 6).
Interestingly, RMAbs targeting the same region of gp120 tend to
cluster to forman independent subtree. For example, heavy chains
and light chains from R15, R35, and R41 (all targeting the C1
region) formed independent subtrees. Similarly, the heavy chains
from three V3-specific RMAbs, R56, R20, and R43, grouped into
another subtree, whereas the light-chain genes of R43 and R20
clustered in a subtree but not with R56. This demonstrates a pro-
cess of clonally related B cell lineage development and affinity
maturation. At the same time, building a phylogenetic tree may
help determine the biological relevance of Env-specific RMAbs.
The breadth and potency of neutralizing activities with indi-
vidual gp120-specific RMAbs. A screening neutralization assay
was conducted using an in-house assay at the University of Mas-
sachusetts Medical School to first identify those RMAbs with pos-
sible neutralizing activities (Table 2). Because this particular rab-
bit was immunized with a clade B gp120 antigen, a standardized
in-house TZM-bl assay was used with a small panel of pseu-
dotyped viruses expressing HIV-1 Env antigens from clade B vi-
ruses representing both neutralization-sensitive (tier 1) and neu-
tralization-resistant (tier 2) primary isolates. Among 12 isolated
RMAbs, 3 showed positive neutralizing activities in this initial
screening assay. V3-specific R56 displayed potent neutralizing ac-
tivity against SF162 (50% inhibitory concentration [IC50] 0.02
g/ml) and to a lesser degree against another sensitive tier 1 virus,
SS1196 (IC50 4.0g/ml), and a tier 2 virus, QH0692 (IC50 8.6
g/ml). C4-specific R53 had potent neutralizing activity against
SF162 (IC50 0.5g/ml) but much lower activity against SS1196
(IC50 31.9g/ml). It is interesting to see that R15, a C1-specific
RMAb, was also able to neutralize SF162 and SS1196, suggesting a
novel neutralizing epitope within the C1 region, at least with re-
spect to certain sensitive viruses.
To further map the breadth of neutralizing activities of
RMAbs, a high-throughput neutralizing assay was conducted at
Monogram, Inc., using its PhenoSense assay system. R53 and R56
were tested against three highly sensitive viruses in addition to 13
FIG7 Binding affinity of rabbitMAbs to JR-FL Env gp120 protein determined
by a ForteBio Octet QKe system. Rabbit MAbs were immobilized on the chip
surface, and the JR-FL gp120 proteins were added in the testing solution. (A)
Rate constants Ka (equilibrium association constant), Kd (dissociation con-
stant), and KD for rabbit MAbs binding to JR-FL gp120, which were obtained
by global fitting of the curves to the 1:1 binding model. (B) The binding kinet-
ics of three selected RMAbs, R56, R53, and R15, to 3-fold serial dilution of
JR-FL gp120 protein.
FIG 8 Protein sequences of heavy- and light-chain variable regions of gp120-specific rabbit MAbs. The sequences are aligned to their corresponding putative
germ line genes. Framework regions (FR) and CDRs are indicated based on IMGT (http://www.imgt.org/) nomenclature. Somatic mutated amino acids
compared to the putative germ line are in red and CDR3 regions in blue.
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primary isolates covering clades A to AE (Table 3). V3-specific
R56 showed neutralizing activities against SF162 and QH0692,
confirming the screening assay results, but was unable to neutral-
ize other pseudotyped viruses. Interestingly, C4-specific R53 neu-
tralized all three sensitive viruses with high potency (IC50 	 1.9
g/ml) and a wide range of primary isolates from various clades,
although at low potency.
Final neutralization assayswere conducted by theComprehen-
sive Antibody Vaccine Immune Monitoring Consortium
(CAVIMC) of the Collaboration for AIDS Vaccine Discovery
(CAVD) program supported by the Bill & Melinda Gates Foun-
dation. RMAb R56, R53, and R15 were tested against a panel of
well-characterized pseudotyped viruses expressing Env from a
wide range of primaryHIV-1 isolates, including 19 tier 1 viruses (2
cladeA, 7 cladeB, 6 cladeC, 1 cladeAE, and 3 cladeAG) and 25 tier
2 viruses (3 clade A, 6 clade B, 3 clade C, 6 clade AE, 3 clade AG, 2
clade BC, and 2 cladeG) (Table 4). V3-specific R56 showed potent
neutralizing activities (IC50 titer	 1 g/ml) against tier 1 clade B
virus SF162.LS, clade C virus MW965.26, and clade AG virus
DJ263.8, while it exhibited moderate to low neutralizing activities
against three tier 1 clade B viruses (SS1196.1, Bal.26, and
Bx.08.16), one tier 1 clade C virus (TV1.21), one clade AE virus
(Th023.6), and one cladeAGvirus (T271-11). C4-specificR53was
also able to neutralize 3 tier 1 viruses (SF162.LS, MW965.26, and
Bx08.16) and 1 tier 2 virus (Thro4156.18) at low potency. No
other viruses on this panel were neutralized by R53. C1-specific
R15was able to neutralize seven tier 1 viruses, including SF162.LS,
SS1196.1, and Bx.08.16 (clade B), MW965.26 and TV1.21 (both
are clade C), TH023 (clade AE), and 242-14 (clade AG), and 1
clade C tier 2 virus, ZM135M.PL10a.
TABLE 1 Characteristics of the variable region of heavy chains and light chains of the vaccine-elicited rabbit MAbs
Epitope RMAb
Heavy chain Light chain
IGHV IGHJ
CDR3
length
(aa)
IGKV IGKJ
CDR3
length
(aa)
Germ
line
Mutation
(%) Germ line
Mutation
(%) Germ line
Mutation
(%)
Germ
line
Mutation
(%)
V3 R56 S40*01 6 4*01 9 6 S15*01 9 2*01 10 13
R20 S40*01 6 4*01 5 23 S3*01 8 2*01 3 12
R43 S40*01 6 4*01 6 6 S37*01 8 2*01 3 11
C4 R53 S40*01 10 4*01 9 17 S49*01 9 2*01 13 15
C1 R15 S40*01 27 4*01 11 6 S33*01 12 2*01 10 10
R35 S40*01 26 4*01 11 6 S52*01 10 2*01 3 9
R41 S40*01 26 4*01 11 6 S52*01 9 2*01 9 10
C5 R13 S45*01 5 4*01 9 6 S15*01 11 2*01 8 12
Conformational/unknown R27 S40*01 23 4*01 15 15 S10*01 11 2*01 10 10
R28 S40*01 10 4*01 or 2*01 11 6 S52*01 9 2*01 10 13
R31 S45*01 22 2*01 12 14 S52*01 or S64*01 7 2*01 5 11
R52 S40*01 8 4*01 or 4*02 3 20 S3*01 8 2*01 3 12
TABLE 2 Neutralization titers of rabbit MAbs by in-house TZM-bl
assaya
a Data represent IC50 values in g/ml. Red,	1 g/ml; orange,
1 to	10; yellow,

10 to	50.
TABLE 3 Neutralization titers of rabbit
MAbs by PhenoSense assay at Monogram
Biosciencesa
a Data represent IC50 values in g/ml. Orange,
1
to	10 g/ml; yellow,
10 to	50.
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Comparing the neutralization results determined by different
laboratories, the Monogram PhenoSense assay revealed that R53
had broader neutralization activities against some tier 2 viruses
but that none of themwere neutralized by R53 in the in-house test
andCAVIMC assay. This discrepancymay be due to differences in
target cells and assay systems: the Monogram PhenoSense assay
used U87 cells, while both the CAVIMC test and the in-house test
used TZM-bl cells. Of note, although PVO.4 was used as a tier 2
virus, it was usually considered a tier 3 virus and was neutralized
by R53 at relatively high potency. Several tier 1 isolates, such as
SS1196 and 6535, are much less sensitive to neutralization than
the highly sensitive SF162 strain. R56 and R15 were able to neu-
tralize SS1196 in both the in-house test and the CAVIMC test,
while the R53 result was positive in the in-house test.
DISCUSSION
Humanmonoclonal antibodies against HIV-1 Env have played an
important role in helping scientists understand the structural fea-
tures of potential immunogen designs (34). During the first 20
years of HIV research, only four broadly cross-reactive neutraliz-
ing HMAbs (2F5, 4E10, 2G12, and b12) have been identified from
HIV-1-infected individuals via the traditional Epstein-Barr virus
(EBV) transformation or phage display library technologies (35–
38). There are also V3-specific human MAbs that can neutralize
multiple HIV-1 isolates (39, 40), but, in general, the breadth of
neutralizing activities is more limited for V3 MAbs than for the
four MAbs mentioned above.
New progress in antigen-specific single B cell sorting (32, 41),
high-throughput microneutralization screens (42), and deep se-
quencing of Ig genes (43) has producedmore broadly neutralizing
Abs (bnAbs) in recent years. These included those targeting CD4
binding sites such as VRC01 to VRC03 (41), PGV04 (44), and
HAAD motif (43) antibodies. The discovery of PG9 and PG16
revealed new bnAb targets at V1 and V2 or the quaternary confor-
mational epitopes (42, 45), whichwere confirmed by other similar
MAbs, such as CH01 to CH04 (46) and PGT141 to PGT145 (47).
Another new group of bnAbs, exemplified by PGT125 to PGT128
and PGT130 and PGT131, recognized the C-terminal part of the
V3 epitope along with two conserved glycans (47).
One caveat concerning these bnAbs is that they were isolated
from chronically infected individuals. Therefore, it is not clear
whether findings from infected humans can be directly translated
into vaccines designed to be tested in a healthy uninfected human
population. In vaccine settings, much lower immunogen dosing
and a shorter exposure time are used for the healthy population
than for those with chronic HIV-1 infection. The unique features
of Env-specific B cells observed in HIV-1-infected patients, such
as hyperactivation of B cells and continuously elevated immuno-
globin levels (48), which are responsible for the high degree of
somatic mutation, long CDR3, and high autoreactivity of Env-
specific antibodies, are lacking in healthy humans. Recently, a
small panel of antibodies isolated from the RV144 clinical trial
vaccines was reported (8). They targeted the V2 region and have
only modest neutralization, and yet they may be correlated to
protection (2).
Such progress indicates that (i) there is a need to model future
HIV vaccine designs according to these novel human bnAbs and
(ii) further investigation of the full spectrum of antibodies elicited
by HIV vaccines is warranted to understand whether there are
additional targets on Env that have not been discovered. More
importantly, these new studies have to be first conducted in ani-
mal models before the next generation of HIV vaccines can be
tested in themore expensive and time-consuming human studies.
Therefore, production of MAb should be included in such pre-
clinical studies to investigate the functional and genetic differ-
ences between infection-elicited MAbs and vaccine-induced
MAbs.
Unfortunately, experience in producing high-quality HIV-1
Env-specific MAb from animal models is limited. Recently, a
panel of CD4bs-directed macaque MAbs elicited by an Env vac-
cine was identified (49) but the high cost of NHP studies prevents
the wide adoption of this system. Historically, murineMAbs were
unable to achieve good neutralizing activities, partially due to the
TABLE 4 Neutralization titers of rabbit MAbs by TZM-bl assay at CAVIMCa
a Data represent IC50 values in g/ml. Red,	1 g/ml; orange,
1 to	10; yellow,
10 to	50.
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poor efficacy in generating a long CDR3 in mouse MAbs (17, 18).
Transgenic mouse systems expressing human antibodies are well
established; however, many of these systems are under the control
of major pharmaceutical companies, preventing scientists not af-
filiated with these companies from having easy access to these
models due to intellectual property barriers. Newly developed hu-
manized mice models are making progress in HIV infection stud-
ies, including the analysis of T cell responses, but their use for B
cell and antibody development has not been fully developed
(63, 64).
Results presented in this report established the feasibility of
producing high-quality Env-specific and potentially functional
rabbit MAbs. Rabbit is an attractive model to study antibody re-
sponses to a wide range of emerging infectious diseases vaccines,
including HIV-1 vaccines (9, 10, 12, 13, 50, 51). Rabbits share
features in B cell development similar to those inmice and human
and those of gut-associated lymphoid tissue (GALT) species, such
as chickens, sheep, and cows (52). B lymphopoiesis in rabbit oc-
curs in a manner similar to that in the human and mice classical
pathway in the bonemarrow; however, since rabbit is amember of
the GALT species, rabbit B lymphopoiesis terminates during early
development (53). The exogenous antigen further expands and
diversifies B cells in GALT species through somatic hypermuta-
tion and gene conversion. Furthermore, phylogenetic analysis
showed that human variable heavy-chain (VH) genes can be di-
vided into threemajor groups, A, B, andC, and all rabbit VHgenes
are closely related to one another and form one monophyletic
group, which is included in VH group C (54). Among those VH
genes, most rabbit B lineage cells rearranged the same VH gene,
VH1,which encodes theVHa allotypic sequence, and rabbits pref-
erentially use it to produce functional antibodies (55). The rabbit
humoral system can serve as a simplified testing platform to study
the evolution pathway of antibody genes, since rabbit adopted a
much less complicated germ line usage than mouse and human.
On the other hand, it was speculated that no VRC01-like antibody
would be raised in rabbits due to the lack of an optimal germ line
VH segment (56).
The phylogenetic analysis suggests that the human and rabbit
Ig genes evolved at nearly the same rate. In contrast, most mouse
genes evolved considerably faster than human and rabbit genes
(54). Gene conversion and somatic hypermutation not only occur
in the germinal center (GC) of the young rabbit appendix but are
also used for diversification during the immune response in sec-
ondary lymphoid tissues, such as the spleen (57). Rabbit B cells see
antigen similarly to cells of the human immune system (58). A
rabbit hybridoma fusion partner was developed previously (20),
and optimization of the traditional rabbit fusion partner cells and
fusion methods greatly facilitated the generation of monoclonal
antigen-specific rabbit hybridoma cell lines (US patents 7,575,896
B2 [21] and 7,732,168 B2 [22]), allowing relatively efficient pro-
duction of RMAbs and use in our current study as a contracted
service.
In this first report of HIV-1 Env-specific rabbit MAb, a wide
diversity of epitopes was identified from a single immunized rab-
bit, which showed high levels of serum polyclonal antibodies
against the autologous JR-FL gp120 antigen. Besides the common
V3 loop-specific rabbit MAbs, other rabbit MAbs were produced
against both linear epitopes at either theN-terminal orC-terminal
region of gp120 and conformational epitopes. Several epitopes
were not previously known. At the time of this study, the role of
V2-specific antibodies was not known; therefore, efforts were not
devoted to cloning V2-specific RMAbs in this study. However,
serum from this rabbit did show positive antibody responses, rec-
ognizing gp70-V1V2 antigen and indicating the presence of V2-
specific antibodies.
Three of 12 RMAbs cloned in this pilot study showed positive
neutralizing activities. R15 indicated a previously unknown neu-
tralizing epitope in the C1 region of Env, as it was able to neutral-
ize several viral isolates across subtypes B, C, AE, and AG, al-
though these viruses are from tier 1 groups and the potency of R15
was low.V3-specificR56 demonstrated high potency against those
viral isolates that were sensitive to V3 neutralization, but the
breadth of the activity of R56 was limited, as would be expected
from MAbs recognizing the tip of the V3 loop.
The third neutralizingMAb, R53, was the only one in this pilot
study that was able to bind all five gp120 antigens from subtype A
to subtype E and also showed broad neutralizing activities in
Monogram assays despite low potency. Interestingly, previous
studies reported that several murine MAbs (28), as well as rat
MAbs (27), isolated from gp120 protein immunization were able
to prevent gp120 binding to CD4. They mainly bound to a region
on aa 430 to 447 of the C4 region, which is now known as part of
the Env bridging sheet. Crystal structure analysis showed that R53
actually binds to the beta strand 21 region within the bridging
sheet (data not shown). The bridging sheet, along with the inter-
face of the outer domain and interdomain of Env, composes the
CD4 binding site. Upon CD4 binding, the bridging sheet under-
goes a conformational change and enables the formation and ex-
posure of the coreceptor binding site. Given the broad reactivity of
R53 to a wide range of primary gp120 proteins across different
subtypes and its ability to neutralize multiple tier 1 pseudoviruses
from different clades, future Env vaccine studies should further
investigate the protection potential of this class of bridging sheet-
targeting antibodies.
In this pilot study, RMAbs were first screened by conventional
ELISA against recombinant monomer gp120 antigens. Screening
based on recognition of viral particles or positive neutralizing an-
tibody activities will improve the chance of identifyingmore func-
tionally relevant MAbs. Furthermore, since the study was limited
by the cost restraints associated with the contracted service used,
not all gp120-positive hybridomas from the initial screening were
further cloned, which reduced the understanding of the full spec-
trum of gp120-specific RMAbs elicited by immunization. Alter-
native technologies that can isolate individual gp120-positive B
cells, similar to those developed for human MAbs, should be ap-
plied to RMAb production in future studies.
Studies of HIV-1-specific human MAbs have suggested that
somatic hypermutation and unusually long heavy-chain CDR3, as
two key indicators for affinitymaturation, are usually required for
broad and potent neutralizing activities of humanMAbs (59–62).
Rabbit MAbs identified in the current study showed various de-
grees of hypermutation and lengths of CDR3, suggesting that
HIV-1 vaccines delivered in the current prime-boost format were
able to initiate the antibody maturation process. It is not known
whether the low potency observed in several neutralizing RMAbs
could be improved if the affinity maturation process were further
enhanced, such as by a different adjuvant. Also, the current study
examined the status of affinity maturation only at the end of a full
vaccination schedule. Observing the induction of gp120-specific
antibody responses throughout the process starting from time
Chen et al.
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points before immunization or early in immunization, by using
the new RMAb platform, will provide more insights into this pro-
cess. It is also possible that the observed high degree of somatic
mutations in the derived MAbs is due to the multiple immuniza-
tions at the end, which deserves future study.
As learned from studies following the RV144 trial, antibody
activities detected in vitro can link to correlates of immune pro-
tection, and identifying the effector MAbs would be helpful to
evaluate vaccine-elicited humoral immune response. Isolation of
MAbs frompreclinical vaccine studies using small-animal or non-
human primate models will help us understand the antibody re-
sponse and B cell development driven by immunization. The
RMAb platform described in the current report will provide a
useful tool to achieve such goals.
ACKNOWLEDGMENTS
The study reported here was funded in part by NIH grants AI082274,
AI082676, AI065250, and AI087191 and the Bill & Melinda Gates Foun-
dation Collaboration for AIDS Vaccine Discovery/Comprehensive Anti-
body-Vaccine Immune Monitoring Consortium, grant OPP1033112.
We thank Jill M. Serrano for critical reading and editing of the man-
uscript.
REFERENCES
1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J,
Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M,
Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL,
Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Mi-
chael NL, Kunasol P, Kim JH, MOPH-TAVEG Investigators. 2009.
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in
Thailand. N. Engl. J. Med. 361:2209–2220.
2. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD,
Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao
HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H,
DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML,
Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA,
Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL,
Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S,
Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis
of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275–1286.
3. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E,
Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H,
Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao
H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M,
O’Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V,
O’Connell RJ, de Souza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML,
McLellan JS, Georgiev I, Kwong PD, Carlson JM, Michael NL, Schief
WR, Gilbert PB, Mullins JI, Kim JH. 2012. Increased HIV-1 vaccine
efficacy against viruses with genetic signatures in EnvV2.Nature 490:417–
420.
4. Doria-Rose NA, Klein RM, Manion MM, O’Dell S, Phogat A,
Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R,
Nason M, Wyatt RT, Mascola JR, Connors M. 2009. Frequency and
phenotype of human immunodeficiency virus envelope-specific B cells
frompatients with broadly cross-neutralizing antibodies. J. Virol. 83:188–
199.
5. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba
NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS,
Morris L, CAPRISA002 Study Team. 2011. The neutralization breadth of
HIV-1 develops incrementally over four years and is associated with
CD4 T cell decline and high viral load during acute infection. J. Virol.
85:4828–4840.
6. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell
Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. 2009. Factors
associated with the development of cross-reactive neutralizing antibodies
during human immunodeficiency virus type 1 infection. J. Virol. 83:757–
769.
7. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman
JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee
DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG,
Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE,
Burton DR, Koff WC. 2009. Human immunodeficiency virus type 1 elite
neutralizers: individuals with broad and potent neutralizing activity iden-
tified by using a high-throughput neutralization assay together with an
analytical selection algorithm. J. Virol. 83:7337–7348.
8. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody
MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ,
Montefiori DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S,
Letvin NL, Karasavvas N, Yang ZY, Dai K, Pancera M, Gorman J,
Wiehe K, Nicely NI, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J,
Pitisuttithum P, Tartaglia J, Sinangil F, Kim JH, Michael NL, Kepler
TB, Kwong PD, Mascola JR, Nabel GJ, Pinter A, Zolla-Pazner S, Haynes
BF. 2013. Vaccine induction of antibodies against a structurally heteroge-
neous site of immune pressure within HIV-1 envelope protein variable
regions 1 and 2. Immunity 38:176–186.
9. Vaine M, Wang S, Hackett A, Arthos J, Lu S. 2010. Antibody responses
elicited through homologous or heterologous prime-boost DNA and pro-
tein vaccinations differ in functional activity and avidity. Vaccine 28:
2999–3007.
10. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S,
Chou TH, Montefiori DC, Lu S. 2005. Enhanced immunogenicity of
gp120 protein when combined with recombinant DNA priming to gener-
ate antibodies that neutralize the JR-FL primary isolate of human immu-
nodeficiency virus type 1. J. Virol. 79:7933–7937.
11. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen
S, Green S, Rothman AL, Ennis FA, Arthos J, Pal R, Markham P, Lu S.
2008. Cross-subtype antibody and cellular immune responses induced by
a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human
volunteers. Vaccine 26:3947–3957.
12. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S.
2008. Improved induction of antibodies against key neutralizing epitopes
by human immunodeficiency virus type 1 gp120 DNA prime-protein
boost vaccination compared to gp120 protein-only vaccination. J. Virol.
82:7369–7378.
13. Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, McElrath
MJ, Lu S. 2010. Profiles of human serum antibody responses elicited by
three leading HIV vaccines focusing on the induction of Env-specific an-
tibodies. PLoS One 5:e13916. doi:10.1371/journal.pone.0013916.
14. Hellerstein M, Xu Y, Marino T, Lu S, Yi H, Wright ER, Robinson HL.
2012. Co-expression of HIV-1 virus-like particles and granulocyte-
macrophage colony stimulating factor by GEO-D03 DNA vaccine. Hum.
Vaccin Immunother. 8:1654–1658.
15. Puri R, Suzuki T, Yamakawa K, Ganesh S. 2009. Hyperphosphorylation
and aggregation of Tau in laforin-deficient mice, an animal model for
Lafora disease. J. Biol. Chem. 284:22657–22663.
16. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE,
O’Banion MK. 2007. Sustained hippocampal IL-1 beta overexpression
mediates chronic neuroinflammation and ameliorates Alzheimer plaque
pathology. J. Clin. Invest. 117:1595–1604.
17. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP,
Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. 2004. HIV vaccine design
and the neutralizing antibody problem. Nat. Immunol. 5:233–236.
18. Gao F, Scearce RM, Alam SM, Hora B, Xia S, Hohm JE, Parks RJ,
Ogburn DF, Tomaras GD, Park E, Lomas WE, Maino VC, Fiscus SA,
Cohen MS, Moody MA, Hahn BH, Korber BT, Liao HX, Haynes BF.
2009. Cross-reactive monoclonal antibodies to multiple HIV-1 subtype
and SIVcpz envelope glycoproteins. Virology 394:91–98.
19. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J,
Simmonds P, Clapham PR. 2004. Biological analysis of human immu-
nodeficiency virus type 1 R5 envelopes amplified from brain and lymph
node tissues of AIDS patients with neuropathology reveals two distinct
tropism phenotypes and identifies envelopes in the brain that confer an
enhanced tropism and fusigenicity for macrophages. J. Virol. 78:6915–
6926.
20. Spieker-Polet H, Sethupathi P, Yam PC, Knight KL. 1995. Rabbit
monoclonal antibodies: generating a fusion partner to produce rabbit-
rabbit hybridomas. Proc. Natl. Acad. Sci. U. S. A. 92:9348–9352.
21. Yu GL. August 2009. Cell fusion method. US patent 7,575,896 B2.
22. Pytela R, Zhu W, Ke Y, Qian R, Au HC. June 2010. Fusion partner for
production of monoclonal rabbit antibodies. US patent 7,732,168 B2.
23. Huson DH, Richter DC, Rausch C, Dezulian T, Franz M, Rupp R. 2007.
Rabbit MAb Platform for HIV-1 Vaccine Design
September 2013 Volume 87 Number 18 jvi.asm.org 10241
 o
n
 N
ovem
ber 17, 2014 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
Dendroscope: an interactive viewer for large phylogenetic trees. BMC
Bioinformatics 8:460. doi:10.1186/1471-2105-8-460.
24. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G,
Bellahcene F, Wu Y, Gemrot E, Brochet X, Lane J, Regnier L, Ehren-
mann F, Lefranc G, Duroux P. 2009. IMGT, the international ImMuno-
GeneTics information system. Nucleic Acids Res. 37:D1006–D1012.
25. Montefiori DC. 2004. Evaluating neutralizing antibodies against HIV,
SIV and SHIV in luciferase reporter gene assays, p 1–15. In Coligan JE,
Kruisbeek AM, Margullies DH, Shevach EM, Strober W (ed), Current
protocols in immunology, vol 12. John Wiley, Hoboken, NJ.
26. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK,
Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U,
Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders
RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore
JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson
IA. 2011. A potent and broad neutralizing antibody recognizes and pen-
etrates the HIV glycan shield. Science 334:1097–1103.
27. Cordell J, Moore JP, Dean CJ, Klasse PJ, Weiss RA, McKeating JA.
1991. Rat monoclonal antibodies to nonoverlapping epitopes of human
immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virol-
ogy 185:72–79.
28. Sun NC, Ho DD, Sun CR, Liou RS, Gordon W, Fung MS, Li XL, Ting
RC, Lee TH, Chang NT, Chang TW. 1989. Generation and character-
ization of monoclonal antibodies to the putative CD4-binding domain of
human immunodeficiency virus type 1 gp120. J. Virol. 63:3579–3585.
29. Palker TJ, Matthews TJ, Clark ME, Cianciolo GJ, Randall RR, Langlois
AJ, White GC, Safai B, Snyderman R, Bolognesi DP, Haynes BF. 1987.
A conserved region at the COOH terminus of human immunodeficiency
virus gp120 envelope protein contains an immunodominant epitope.
Proc. Natl. Acad. Sci. U. S. A. 84:2479–2483.
30. Cheung WC, Beausoleil SA, Zhang X, Sato S, Schieferl SM, Wieler JS,
Beaudet JG, Ramenani RK, Popova L, Comb MJ, Rush J, Polakiewicz
RD. 2012. A proteomics approach for the identification and cloning of
monoclonal antibodies from serum. Nat. Biotechnol. 30:447–452.
31. Moody MA, Zhang R, Walter EB, Woods CW, Ginsburg GS, McClain
MT, Denny TN, Chen X, Munshaw S, Marshall DJ, Whitesides JF,
Drinker MS, Amos JD, Gurley TC, Eudailey JA, Foulger A, DeRosa KR,
Parks R, Meyerhoff RR, Yu JS, Kozink DM, Barefoot BE, Ramsburg EA,
Khurana S, Golding H, Vandergrift NA, Alam SM, Tomaras GD, Kepler
TB, Kelsoe G, Liao HX, Haynes BF. 2011. H3N2 influenza infection
elicits more cross-reactive and less clonally expanded anti-hemagglutinin
antibodies than influenza vaccination. PLoS One 6:e25797. doi:10.1371
/journal.pone.0025797.
32. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng
NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed
R, Wilson PC. 2008. Rapid cloning of high-affinity human monoclonal
antibodies against influenza virus. Nature 453:667–671.
33. Popkov M, Mage RG, Alexander CB, Thundivalappil S, Barbas CF, III,
Rader C. 2003. Rabbit immune repertoires as sources for therapeutic
monoclonal antibodies: the impact of kappa allotype-correlated variation
in cysteine content on antibody libraries selected by phage display. J. Mol.
Biol. 325:325–335.
34. Clapham PR, Lu S. 2011. Vaccinology: precisely tuned antibodies nab
HIV. Nature 477:416–417.
35. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW,
Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al. 1994. Efficient
neutralization of primary isolates of HIV-1 by a recombinant human
monoclonal antibody. Science 266:1024–1027.
36. Conley AJ, Kessler JA, II, Boots LJ, Tung JS, Arnold BA, Keller PM,
Shaw AR, Emini EA. 1994. Neutralization of divergent human immuno-
deficiency virus type 1 variants and primary isolates by IAM-41 to 2F5, an
anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A.
91:3348–3352.
37. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N,
Srinivasan K, Sodroski J, Moore JP, Katinger H. 1996. Human mono-
clonal antibody 2G12 defines a distinctive neutralization epitope on the
gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol.
70:1100–1108.
38. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley
JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW. 2001.
Broadly neutralizing antibodies targeted to the membrane-proximal ex-
ternal region of human immunodeficiency virus type 1 glycoprotein gp41.
J. Virol. 75:10892–10905.
39. Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self S, Williams C,
Gorny MK, Zolla-Pazner S. 2010. Anti-V3 monoclonal antibodies dis-
play broad neutralizing activities against multiple HIV-1 subtypes. PLoS
One 5:e10254. doi:10.1371/journal.pone.0010254.
40. Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P,
GornyMK. 2004. The cross-clade neutralizing activity of a humanmono-
clonal antibody is determined by the GPGRV3motif of HIV type 1. AIDS
Res. Hum. Retroviruses 20:1254–1258.
41. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou
T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O’Dell S, Louder MK,
Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD,
Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of
envelope identifies broadly neutralizing humanmonoclonal antibodies to
HIV-1. Science 329:856–861.
42. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL,
Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH,
Olsen OA, Frey SM, Hammond PW, Protocol G Principal Investiga-
tors, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR.
2009. Broad and potent neutralizing antibodies from an African donor
reveal a new HIV-1 vaccine target. Science 326:285–289.
43. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY,
Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad
F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS,
Bjorkman PJ, Chait BT, Nussenzweig MC. 2011. Sequence and struc-
tural convergence of broad and potent HIV antibodies that mimic CD4
binding. Science 333:1633–1637.
44. Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X,
Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P,
Burton DR. 2012. PGV04, an HIV-1 gp120 CD4 binding site antibody, is
broad and potent in neutralization but does not induce conformational
changes characteristic of CD4. J. Virol. 86:4394–4403.
45. Kimura T, Wang XH, Williams C, Zolla-Pazner S, Gorny MK. 2009.
Human monoclonal antibody 2909 binds to pseudovirions expressing
trimers but not monomeric HIV-1 envelope proteins. Hum. Antibodies
18:35–40.
46. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E,
Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M,
Yongping Y, Zhang B, Zhu J, Kwong PD, O’Dell S, Mascola JR, Wu L,
Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G,
Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras
GD, Alam SM, Liao HX, Haynes BF. 2011. Analysis of a clonal lineage of
HIV-1 envelope V2/V3 conformational epitope-specific broadly neutral-
izing antibodies and their inferred unmutated common ancestors. J. Virol.
85:9998–10009.
47. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP,
Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond
PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek
MD, Protocol G Principal Investigators, Koff WC, Wilson IA, Burton
DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple
highly potent antibodies. Nature 477:466–470.
48. De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E,
Narita M, Grutzmeier S, Sonnerborg A, Chiodi F. 2004. Mechanisms of
hypergammaglobulinemia and impaired antigen-specific humoral immu-
nity in HIV-1 infection. Blood 103:2180–2186.
49. Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, O’Dell S, Feng Y,
Mascola JR, Wyatt RT, Karlsson Hedestam GB. 2012. High-resolution
definition of vaccine-elicited B cell responses against the HIV primary
receptor binding site. Sci. Transl. Med. 4:142ra96. doi:10.1126
/scitranslmed.3003752.
50. Wang S, Chou TH, Sakhatskyy PV, Huang S, Lawrence JM, Cao H,
Huang X, Lu S. 2005. Identification of two neutralizing regions on the
severe acute respiratory syndrome coronavirus spike glycoprotein pro-
duced from the mammalian expression system. J. Virol. 79:1906–1910.
51. Wang S, Taaffe J, Parker C, Solorzano A, Cao H, Garcia-Sastre A, Lu S.
2006. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influ-
enza A viruses require different antigen designs for the induction of opti-
mal protective antibody responses as studied by codon-optimized HA
DNA vaccines. J. Virol. 80:11628–11637.
52. Mage RG, Lanning D, Knight KL. 2006. B cell and antibody repertoire
development in rabbits: the requirement of gut-associated lymphoid tis-
sues. Dev. Comp. Immunol. 30:137–153.
53. Jasper PJ, Zhai SK, Kalis SL, Kingzette M, Knight KL. 2003. B lympho-
Chen et al.
10242 jvi.asm.org Journal of Virology
 o
n
 N
ovem
ber 17, 2014 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
cyte development in rabbit: progenitor B cells and waning of B lympho-
poiesis. J. Immunol. 171:6372–6380.
54. Su C, Nei M. 1999. Fifty-million-year-old polymorphism at an immuno-
globulin variable region gene locus in the rabbit evolutionary lineage.
Proc. Natl. Acad. Sci. U. S. A. 96:9710–9715.
55. Knight KL, Becker RS. 1990. Molecular basis of the allelic inheritance of
rabbit immunoglobulin VH allotypes: implications for the generation of
antibody diversity. Cell 60:963–970.
56. West AP, Jr, Diskin R, Nussenzweig MC, Bjorkman PJ. 2012. Structural
basis for germ-line gene usage of a potent class of antibodies targeting the
CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. U. S. A. 109:
E2083–E2090.
57. Mage RG, Sehgal D, Schiaffella E, Anderson AO. 1999. Gene-conversion
in rabbit B-cell ontogeny and during immune responses in splenic germi-
nal centers. Vet. Immunol. Immunopathol. 72:7–15.
58. McClain MT, Lutz CS, Kaufman KM, Faig OZ, Gross TF, James JA.
2004. Structural availability influences the capacity of autoantigenic
epitopes to induce a widespread lupus-like autoimmune response. Proc.
Natl. Acad. Sci. U. S. A. 101:3551–3556.
59. Bonsignori M, Alam SM, Liao HX, Verkoczy L, Tomaras GD, Haynes
BF, Moody MA. 2012. HIV-1 antibodies from infection and vaccination:
insights for guiding vaccine design. Trends Microbiol. 20:532–539.
60. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R,
Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam
SM. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutral-
izing HIV-1 antibodies. Science 308:1906–1908.
61. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS,
Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T,
Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD,
Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1
by a gp41-specific human antibody. Nature 491:406–412.
62. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo
NS, Louder M, McKee K, O’Dell S, Perfetto S, Schmidt SD, Shi W, Wu
L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA,
Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC,
Doria-Rose N, Connors M, NISC Comparative Sequencing Program,
Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR.
2011. Focused evolution of HIV-1 neutralizing antibodies revealed by
structures and deep sequencing. Science 333:1593–1602.
63. Shultz LD, Ishikawa F, Greiner DL. 2007. Humanized mice in transla-
tional biomedical research. Nat. Rev. Immunol. 7:118–130.
64. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. 2012. Human-
ized mice for immune system investigation: progress, promise and chal-
lenges. Nat. Rev. Immunol. 12:786–798.
65. Pan R, Sampson JM, Chen Y, Vaine M, Wang S, Lu S, Kong X-P. 2013.
Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can
mimic the antigen-binding modes of antibodies derived from HIV-1-
infected humans. J. Virol. 87:10221–10231.
Rabbit MAb Platform for HIV-1 Vaccine Design
September 2013 Volume 87 Number 18 jvi.asm.org 10243
 o
n
 N
ovem
ber 17, 2014 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
